Business Insider
My Markets Watchlist
Markets Stocks

BeiGene Ltd (spons. ADRs) Stock , ONC

252.52 -3.12 -1.22%
03:45:08 PM BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Thursday morning 07/10/2025 the BeiGene Ltd (spons. ADRs) share started trading at the price of $252.91. Compared to the closing price on Wednesday 07/09/2025 on BTT of $255.64, this is a drop of 1.07%. There are 109.60 M shares outstanding in BeiGene Ltd (spons. ADRs), which values the company at $22.27 B.
Is BeiGene stock a Buy, Sell or Hold? BeiGene stock has received a consensus rating of buy. The average rating score is and is based on 21 buy ratings, 4 hold ratings, and 0 sell ratings.
What was the 52-week low for BeiGene stock? The low in the last 52 weeks of BeiGene stock was 143.36. According to the current price, BeiGene is 176.21% away from the 52-week low.
What was the 52-week high for BeiGene stock? The high in the last 52 weeks of BeiGene stock was 287.79. According to the current price, BeiGene is 87.78% away from the 52-week high.
What are analysts forecasts for BeiGene stock? The 25 analysts offering price forecasts for BeiGene have a median target of 282.11, with a high estimate of 350.00 and a low estimate of 152.50. The median estimate represents a 89.54 difference from the last price of 252.61.

BeiGene Stock Snapshot

252.47
Bid
3.00
Bid Size
254.05
Ask
100.00
Ask Size
7/10/2025
Date
3:45 PM
Time
4,456.00
Volume
255.64
Prev. Close
252.91
Open
28.02 B
Market Cap in USD
109.60 M
Number of Shares
109.60 M
Total Number of Shares
250.65
Day Low
254.81
Day High
252.52
143.36
52 Week Low
287.79
52 Week High
252.52
0.00
Dividend in USD
0.00
Dividend Yield
99.11
Free Float in %
-6.12
EPS in USD
31.22
Book Value per Share in USD
-1.34
Cash Flow per Share in USD

Historical Prices for BeiGene

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

BeiGene Analyst Data

Total Analysts: 25
Buy Ratings: 21 Neutral Ratings: 4 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 152.50 Median: 282.11 Highest: 350.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

BeiGene Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
06/27/25 Morgan Stanley
Maintained Buy $330
06/27/25 J.P. Morgan
Maintained Buy $321
06/27/25 RBC Capital Markets
Maintained Buy $311
05/08/25 RBC Capital Markets
Maintained Buy $311
05/08/25 Guggenheim
Maintained Buy $350
04/28/25 RBC Capital Markets
Maintained Buy $312
04/24/25 TD Securities
Maintained Buy $334
04/21/25 J.P. Morgan
Maintained Buy $317
04/16/25 Guggenheim
Maintained Buy
04/10/25 Guggenheim
Maintained Buy $348
04/07/25 RBC Capital Markets
Maintained Buy $312
02/28/25 Macquarie Research
Maintained Buy $313
07/09/24 Bank of America Merrill Lynch
Maintained Hold $152.5
04/08/24 Bank of America Merrill Lynch
Maintained Hold $164.300003051758
03/27/24 Bernstein
Maintained Hold $161
02/27/24 Guggenheim
Maintained Buy $345
02/06/24 J.P. Morgan
Maintained Buy $185
10/26/23 Citigroup Corp.
Maintained Buy $285
09/21/23 Citigroup Corp.
Maintained Buy $290
09/20/23 Bank of America Merrill Lynch
Maintained Hold $212
09/12/23 Macquarie Research
Maintained Buy $259
09/12/23 RBC Capital Markets
Maintained Buy $259
08/29/23 Morgan Stanley
Maintained Buy $319
08/17/23 Jefferies & Company Inc.
Maintained Buy $287
08/07/23 J.P. Morgan
Maintained Buy $300
07/17/23 Citigroup Corp.
Maintained Buy $275

BeiGene Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 5,108 6,206 7,221 8,062 9,102
Dividend 0.00 0.43 0.00 - -
Dividend Yield (in %) 0.00 % 0.18 % 0.00 % - -
EPS 1.54 5.55 9.76 12.99 16.81
P/E Ratio 159.25 44.02 25.05 18.82 14.54
EBIT 134 628 1,301 1,917 2,574
EBITDA 275 783 1,501 2,857 4,287
Net Profit 109 545 1,082 1,728 2,405
Net Profit Adjusted 270 632 1,406 2,613 4,189
Pre-Tax Profit 168 637 1,379 2,082 2,915
Pre-Tax Profit Reported 233 746 1,345 1,600 -
EPS (Non-GAAP) ex. SOE 0.96 5.74 9.31 - -
EPS (GAAP) - - 9.89 12.91 14.05
Gross Income 4,350 5,309 6,155 7,466 8,363
Cash Flow from Investing -312 -323 -364 -783 -517
Cash Flow from Operations 346 930 1,576 2,692 3,489
Cash Flow from Financing 84 141 113 -28 -55
Cash Flow per Share 2.43 6.30 12.00 17.68 -
Free Cash Flow 313 786 1,423 1,807 2,611
Free Cash Flow per Share - - 9.30 - -
Book Value per Share 31.68 37.57 50.21 63.15 -
Net Debt -1,506 -2,093 -3,329 -5,297 -
Research & Development Exp. 2,105 2,301 2,443 2,593 2,809
Capital Expenditure 256 261 267 398 417
Selling, General & Admin. Exp. 2,079 2,305 2,401 2,240 2,233
Shareholder’s Equity 3,590 4,344 5,861 10,103 13,787
Total Assets 6,406 7,343 9,150 12,695 17,963
  Previous Quarter
ending 06/30/25 		Current Quarter
ending 09/30/25 		Next Quarter
ending 12/31/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts 11 11 11 29 29
Average Estimate 0.207 USD 0.290 USD 0.795 USD 1.535 USD 5.554 USD
Year Ago -1.150 USD -1.146 USD -1.429 USD -6.124 USD -
Publish Date 8/30/2025 11/6/2025 4/1/2026 - -
Revenue Estimates
No. of Analysts 9 9 9 32 32
Average Estimate 1,235 USD 1,301 USD 1,430 USD 5,108 USD 6,206 USD
Year Ago 929 USD 1,002 USD 1,128 USD 3,810 USD -
Publish Date 8/30/2025 11/6/2025 4/1/2026 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 3,810.24 2,458.78 1,415.92 1,176.28 308.87 428.21 198.22
Change of sales in % 54.96 73.65 20.37 280.83 -27.87 116.03 -16.85
Gross profit on sales 3,091.83 1,994.92 1,066.39 965.89 206.43 338.41 159.62
Gross profit on sales change in % 54.98 87.07 10.41 367.90 -39.00 112.01 -30.24
Operating income -568.20 -1,207.74 -1,788.00 -1,438.74 -1,657.68 -959.89 -705.77
Operating income change in % 52.95 32.45 -24.28 13.21 -72.69 -36.01 -616.83
Income before tax -533.00 -825.84 -1,961.04 -1,438.59 -1,618.19 -943.59 -689.83
Income before tax change in % 35.46 57.89 -36.32 11.10 -71.49 -36.79 -657.52
Income after tax -644.79 -881.71 -2,003.82 -1,413.35 -1,596.91 -948.63 -673.77
Income after tax change in % 26.87 56.00 -41.78 11.49 -68.34 -40.79 -623.67

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 2,592.89 2,267.95 1,995.94 2,402.96 1,731.51 633.93 496.04
Long-term liabilities per share 3.56 4.44 5.14 - 6.63 4.50 3.55
Equity 3,332.22 3,537.33 4,383.36 6,242.99 3,869.24 978.36 1,753.65
Equity change in % -5.80 -19.30 -29.79 61.35 302.12 -44.68 159.66
Balance sheet total 5,925.12 5,805.28 6,379.29 8,645.95 5,600.76 1,612.29 2,249.68
Balance sheet total change in % 2.06 -9.00 -26.22 54.37 247.38 -28.33 114.90

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 36.19 23.55 13.73 12.68 3.70 7.13 3.32
P/E ratio (year end quote, basic EPS) - - - - - - -
P/E ratio (year end quote, diluted EPS) - - - - - - -
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Equity ratio in % 56.24 60.93 68.71 72.21 69.08 60.68 77.95
Debt ratio in % 43.76 39.07 31.29 27.79 30.92 39.32 22.05

BeiGene Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Wang Xiaodong 06/23/2025 1,100.00 607.00 265.35 Sell No
Wang Xiaodong 06/23/2025 507.00 100.00 266.57 Sell No
Wang Xiaodong 06/23/2025 100.00 n/a 267.81 Sell No
Wang Xiaodong 06/23/2025 300.00 1,707.00 263.50 Sell No
OYLER JOHN 06/22/2025 3,074.00 100.00 261.57 Sell No
OYLER JOHN 06/22/2025 100.00 n/a 262.90 Sell No
Wu Xiaobin 06/22/2025 1,363.00 n/a 260.00 Sell No
Wang Lai 06/22/2025 1,028.00 n/a 260.00 Sell No
Wang Lai 06/16/2025 470.00 n/a 251.37 Sell No
OYLER JOHN 06/16/2025 1,460.00 n/a 256.49 Sell No
Wu Xiaobin 06/16/2025 630.00 n/a 250.87 Sell No
Lee Chan Henry 06/15/2025 422.00 n/a 266.50 Sell No
Wang Lai 06/15/2025 1,177.00 470.00 266.40 Sell No
OYLER JOHN 06/15/2025 3,680.00 1,460.00 266.05 Sell No
Wu Xiaobin 06/15/2025 100.00 630.00 266.22 Sell No
Wu Xiaobin 06/15/2025 1,443.00 730.00 265.47 Sell No
Ball Titus B. 06/10/2025 134.00 n/a 258.36 Sell No
Wang Xiaodong 06/09/2025 6,787.00 100.00 264.08 Sell No
Wang Xiaodong 06/09/2025 16,094.00 6,887.00 263.17 Sell No
Wang Xiaodong 06/09/2025 2,901.00 38,859.00 261.20 Sell No
Wang Xiaodong 06/09/2025 15,878.00 22,981.00 262.20 Sell No
Wang Xiaodong 06/09/2025 100.00 n/a 264.85 Sell No
Yi Qingqing 06/09/2025 29,614.00 27,326.00 n/a Sell No
Ball Titus B. 06/09/2025 29,601.00 73,983.00 n/a Buy No
Wang Lai 06/09/2025 86,359.00 1,058,304.00 n/a Buy No

BeiGene Dividend Calendar

Date Name Dividend *yield Currency
2024 BeiGene Ltd (spons. ADRs) 0.00 0.00 USD
2023 BeiGene Ltd (spons. ADRs) 0.00 0.00 USD
2022 BeiGene Ltd (spons. ADRs) 0.00 0.00 USD
2021 BeiGene Ltd (spons. ADRs) 0.00 0.00 USD
2020 BeiGene Ltd (spons. ADRs) 0.00 0.00 USD
2019 BeiGene Ltd (spons. ADRs) 0.00 0.00 USD
2018 BeiGene Ltd (spons. ADRs) 0.00 0.00 USD
2017 BeiGene Ltd (spons. ADRs) 0.00 0.00 USD
2016 BeiGene Ltd (spons. ADRs) 0.00 0.00 USD
2015 BeiGene Ltd (spons. ADRs) - - USD
2014 BeiGene Ltd (spons. ADRs) - - USD
2013 BeiGene Ltd (spons. ADRs) - - USD
*Yield of the Respective Date

BeiGene Calendar

Event Estimate Info Date
Earnings Report 0.207 USD Q2 2025 Earnings Release 08/30/2025
Earnings Report 0.290 USD Q3 2025 Earnings Release 11/06/2025
Earnings Report 0.795 USD Q4 2025 Earnings Release 04/01/2026
Earnings Report 0.614 USD Q1 2026 Earnings Release 04/30/2026
Earnings Report 0.866 USD Q2 2026 Earnings Release 08/21/2026

BeiGene Past Events

Event Actual EPS Info Date
Annual General Meeting -6.124 USD Annual General Meeting 05/21/2025
Earnings Report 0.011 USD Q1 2025 Earnings Release 05/07/2025
Earnings Report -1.429 USD Q4 2024 Earnings Release 03/27/2025
Earnings Report -1.146 USD Q3 2024 Earnings Release 11/12/2024
Earnings Report -1.150 USD Q2 2024 Earnings Release 08/27/2024
Annual General Meeting -8.447 USD Annual General Meeting 06/05/2024
Earnings Report -2.409 USD Q1 2024 Earnings Release 05/08/2024
Earnings Report -3.532 USD Q4 2023 Earnings Release 02/26/2024
Earnings Report 2.014 USD Q3 2023 Earnings Release 11/09/2023
Earnings Report -3.643 USD Q2 2023 Earnings Release 08/25/2023
Annual General Meeting -19.429 USD Annual General Meeting 06/15/2023
Earnings Report -3.345 USD Q1 2023 Earnings Release 05/04/2023
Earnings Report -4.292 USD Q4 2022 Earnings Release 03/29/2023
Earnings Report -5.388 USD Q3 2022 Earnings Release 11/09/2022
Earnings Report -5.559 USD Q2 2022 Earnings Release 08/26/2022
Annual General Meeting -15.233 USD Annual General Meeting 06/22/2022
Earnings Report -4.238 USD Q1 2022 Earnings Release 05/05/2022
Earnings Report -6.163 USD Q4 2021 Earnings Release 03/30/2022

BeiGene Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
7
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.
OSZAR »